Literature DB >> 20052471

Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma.

Imran Bhatti1, Oliver Peacock, Altaf K Awan, David Semeraro, Michael Larvin, Richard I Hall.   

Abstract

BACKGROUND: The objective of this study was to compare the prognostic significance of the lymph node ratio (LNR) with the absolute number of affected lymph nodes for resected pancreatic ductal adenocarcinoma.
METHODS: Data were collected from 84 patients who had undergone pancreatoduodenectomy for pancreatic ductal adenocarcinoma over a 10-year period. Patients were categorized into four groups according to the absolute LNR (0, 0-0.199, 0.2-0.299, > or =0.3). Kaplan-Meier and Cox proportional hazard models were used to evaluate the prognostic effect.
RESULTS: An LNR of > or =0.2 (median survival 8.1 vs. 35.7 months with LNR < 0.2; p < 0.001) and > or =0.3 (median survival 5.9 vs. 29.6 months with LNR < 0.3; p < 0.001), tumor size (p < 0.017), positive resection margin (p < 0.001), and nodal involvement (p < 0.001) were found to be significant prognostic markers following univariate analysis. Following multivariate analysis, only LNR at both levels [> or =0.2 (p = 0.05; HR 1.8) and LNR of > or =0.3 (p = 0.01; HR 2.7)] were independent predictors of a poor outcome. The number of lymph nodes examined had no effect on overall survival in either node-positive patients (p = 0.339) or node-negative patients (p = 0.473).
CONCLUSIONS: The LNR represents a stronger independent prognostic indicator than the absolute number of affected lymph nodes in patients with resected pancreatic ductal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20052471     DOI: 10.1007/s00268-009-0336-4

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  23 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Authors:  T M Breslin; K R Hess; D B Harbison; M E Jean; K R Cleary; A P Dackiw; R A Wolff; J L Abbruzzese; N A Janjan; C H Crane; J N Vauthey; J E Lee; P W Pisters; D B Evans
Journal:  Ann Surg Oncol       Date:  2001-03       Impact factor: 5.344

3.  Risk factors associated with earlier age of onset in familial pancreatic carcinoma.

Authors:  Ted A James; David G Sheldon; Ashwani Rajput; Boris W Kuvshinoff; Milind M Javle; Hector R Nava; Judy L Smith; John F Gibbs
Journal:  Cancer       Date:  2004-12-15       Impact factor: 6.860

4.  The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer.

Authors:  Marek Sierzega; Tadeusz Popiela; Jan Kulig; Krystyna Nowak
Journal:  Pancreas       Date:  2006-10       Impact factor: 3.327

Review 5.  Current standards of surgery for pancreatic cancer.

Authors:  N Alexakis; C Halloran; M Raraty; P Ghaneh; R Sutton; J P Neoptolemos
Journal:  Br J Surg       Date:  2004-11       Impact factor: 6.939

6.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

7.  Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma.

Authors:  D Tamandl; K Kaczirek; B Gruenberger; C Koelblinger; J Maresch; R Jakesz; T Gruenberger
Journal:  Br J Surg       Date:  2009-08       Impact factor: 6.939

8.  Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period.

Authors:  Robert Rosenberg; Jan Friederichs; Tibor Schuster; Ralf Gertler; Matthias Maak; Karen Becker; Anne Grebner; Kurt Ulm; Heinz Höfler; Hjalmar Nekarda; Jörg-Rüdiger Siewert
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

9.  Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.

Authors:  Jonathan E Lim; Michael W Chien; Craig C Earle
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

10.  Prognostic factors after resection of pancreatic cancer.

Authors:  Michio Ueda; Itaru Endo; Masayuki Nakashima; Yuta Minami; Kazuhisa Takeda; Kenichi Matsuo; Yasuhiko Nagano; Kuniya Tanaka; Yasushi Ichikawa; Shinji Togo; Chikara Kunisaki; Hiroshi Shimada
Journal:  World J Surg       Date:  2009-01       Impact factor: 3.352

View more
  27 in total

1.  Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection.

Authors:  Robert M Cannon; Ryan LeGrand; Ryaz B Chagpar; Syed A Ahmad; Rebecca McClaine; Hong Jin Kim; Christopher Rupp; Cliff S Cho; Adam Brinkman; Sharon Weber; Emily R Winslow; David A Kooby; Carrie K Chu; Charles A Staley; Ian Glenn; William G Hawkins; Alexander A Parikh; Nipun B Merchant; Kelly M McMasters; Robert C G Martin; Glenda G Callender; Charles R Scoggins
Journal:  HPB (Oxford)       Date:  2012-01-19       Impact factor: 3.647

Review 2.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

3.  Prognostic value of the lymph node ratio after resection of periampullary carcinomas.

Authors:  Shahid G Farid; Gavin A Falk; Daniel Joyce; Sricharan Chalikonda; R Matthew Walsh; Andrew M Smith; Gareth Morris-Stiff
Journal:  HPB (Oxford)       Date:  2012-11-19       Impact factor: 3.647

4.  Clinical and pathologic features influencing survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Cynthia E Weber; Eileen A Bock; Michael G Hurtuk; Gerard J Abood; Jack Pickleman; Margo Shoup; Gerard V Aranha
Journal:  J Gastrointest Surg       Date:  2013-11-23       Impact factor: 3.452

5.  Prognostic value of lymph node ratio in survival of patients with locally advanced rectal cancer.

Authors:  Di Zhou; Ming Ye; Yongrui Bai; Ling Rong; Yanli Hou
Journal:  Can J Surg       Date:  2015-08       Impact factor: 2.089

6.  Less than 12 lymph nodes in the surgical specimen after neoadjuvant chemo-radiotherapy: an indicator of tumor regression in locally advanced rectal cancer?

Authors:  Jaiprakash Gurawalia; Kapil Dev; Sandeep P Nayak; Vishnu Kurpad; Arun Pandey
Journal:  J Gastrointest Oncol       Date:  2016-12

7.  Robotic versus open pancreaticoduodenectomy: a comparative study at a single institution.

Authors:  Nicolas Christian Buchs; Pietro Addeo; Francesco Maria Bianco; Subhashini Ayloo; Enrico Benedetti; Pier Cristoforo Giulianotti
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

Review 8.  Tricks and tips in pancreatoduodenectomy.

Authors:  Anna Pallisera; Rafael Morales; Jose Manuel Ramia
Journal:  World J Gastrointest Oncol       Date:  2014-09-15

9.  N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.

Authors:  Nakul P Valsangkar; Devon M Bush; James S Michaelson; Cristina R Ferrone; Jennifer A Wargo; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2012-12-11       Impact factor: 3.452

10.  Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.

Authors:  Biku J John; Prashant Naik; Alastair Ironside; Brian R Davidson; Guiseppe Fusai; Roopinder Gillmore; Jennifer Watkins; Sakhawat H Rahman
Journal:  HPB (Oxford)       Date:  2013-01-14       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.